key: cord-0838318-vrfm3n93
authors: Haller, Maria C.; Kaiser, Robert A.; Langthaler, Simon; Brandstetter, Clara; Apfalter, Petra; Kerschner, Heidrun; Cejka, Daniel
title: Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients
date: 2022-01-04
journal: Transpl Int
DOI: 10.3389/ti.2021.10026
sha: 7e47b9cd52ca841e3d12df7aded3e08b7818a9e2
doc_id: 838318
cord_uid: vrfm3n93

nan

Anti-S-antibody positivity was detected in 51% of the patients in our study cohort. A higher proportion of mRNA-1273 vaccinated patients achieved antibody-positivity compared to those vaccinated with BNT162b2 (61.6 vs 47.7%, p 0.037, Chi 2 -test). After correction for age, diabetes status, sex, serum albumin and serum creatinine, the odds ratio for anti-S-antibody seroconversion was significantly higher for mRNA-1273 vaccinated patients compared to BNT162b2 in a multivariate regression analysis (odds ratio: 2.12, 95% confidence interval: 1.16 to 3.87, p 0.013, Figure 1 Reasons for a higher rate of seroconversion after mRNA-1273 vaccination compared to BNT162b2 are currently uncertain. Possible explanations include differences in mRNA content per vaccine dose, differences in mRNA modification or differences in the lipid formulation between the vaccines, all of which may influence expression of spike (S)-proteins and therefore immunogenicity. A limitation of this study is the lack of data in cellular immune responses, which may underestimate the immunogenicity of the vaccines. Another limitation is the retrospective nature of this study. However, similar results were recently reported in another observational study on immunogenicity of the mRNA-1273 and BNT162b2 vaccines in patients on renal replacement therapy (7), corroborating our findings.

In conclusion, vaccination with mRNA-1273 is associated with higher odds of anti-S-antibody seroconversion compared to vaccination with BNT162b2 in prevalent kidney transplant recipients.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

The studies involving human participants were reviewed and approved by the Ethics Committee of the Johannes Kepler University Linz, Austria. The patients/participants provided their written informed consent to participate in this study.

Research idea and study design: MH, RK, PA, HK, and DC. Data acquisition: RK, SL, HK, CB, and DC. Data analysis/ interpretation: MH, RK, SL, PA, HK, CB, and DC. Statistical analysis: MH and DC. Supervision or mentorship: DC. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We thank Mrs. Julia Panholzer for valuable administrative assistance and the staff of the renal outpatient clinic of the OKL-Elisabethinen hospital for their support.

The Supplementary Material for this article can be found online at: https://www.frontierspartnerships.org/articles/10.3389/ti.2021. 10026/full#supplementary-material 

Results from the ERA-EDTA Registry Indicate a High Mortality Due to COVID-19 in Dialysis Patients and Kidney Transplant Recipients across Europe

Reduced Humoral Response to mRNA SARS-CoV-2 BNT162b2 Vaccine in Kidney Transplant Recipients without Prior Exposure to the Virus

Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients

Occurrence of Severe COVID-19 in Vaccinated Transplant Patients

Performance Characteristics of Five Immunoassays for SARS-CoV-2: a Head-To-Head Benchmark Comparison

Comparative Performance of Five Commercially Available Serologic Assays to Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers

Humoral and Cellular Immunity to SARS-CoV-2 Vaccination in Renal Transplant versus Dialysis Patients: A Prospective, Multicenter Observational Study Using mRNA-1273 or BNT162b2 mRNA Vaccine